Replies to post #89473 on Biotech Values

[kris_kade]

Bernstein said it had learned that Novartis' generic Sandoz division was setting prices and soliciting pre-orders from U.S. purchasers for its generic form of Lovenox, or enoxaparin.

Agree on NVS not issuing any such statements per se...however could it be that Bernstien conveyed a hightened sense of such 'activity' which market seems to be inferring as approval being imminent ?

It's bit intriguing that Bernstien could or would not comment on MNTA getting the sole approval or not, assuming his information is more than just stemming from inference.

[bridgeofsighs]

I felt compelled to buy some MNTA calls this afternoon.
I bought 100 Mar 17.50 to go along with my shares I needed something that is not so negative. ;)

Still holding SRDX AMLN and MNTA.
I am loaded to the gills with March puts on the SPY on top of the SDS I have been buying. I had been pressing the puts daily as the volatility dropped.